Found 18 articles for: "Alopecia areata"
Patients With Lichen Planopilaris Are at Increased Risk of Skin Cancer
May 2026 | Volume 25 | Issue 5 | Features | 479 | Copyright © May 2026
Treatment or Trigger? The Use of Biologic Therapy for Alopecia Areata
May 2026 | Volume 25 | Issue 5 | Features | 489 | Copyright © May 2026
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
March 2026 | Volume 25 | Issue 3 | Original Article | 204 | Copyright © March 2026
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US ...
Read MoreFrom Bald to Bold: Reversal of Alopecia Totalis in an Adolescent Using Dupilumab Monotherapy
March 2026 | Volume 25 | Issue 3 | Case Reports | 273 | Copyright © March 2026
Introduction: Alopecia areata (AA) is an autoimmune condition marked by non-scarring, patchy hair loss of the scalp which progresses in <10% of cases to alopecia totalis (AT),...
Read MoreBaricitinib-Related Adverse Events in Alopecia Areata and Rheumatoid Arthritis: A Comparative Study
March 2026 | Volume 25 | Issue 3 | Features | 286 | Copyright © March 2026
Alopecia Areata in Skin of Color: Trichoscopic Analysis in Black/African American Patients
July 2025 | Volume 24 | Issue 7 | Features | 708 | Copyright © July 2025
Importance: Alopecia areata (AA) has a higher prevalence in populations with skin of color, yet the trichoscopic features in this population remain underexplored.Alopecia as an Adverse Event of Immune Checkpoint Inhibitor Therapies: Clinical Evidence and Outcomes
March 2025 | Volume 24 | Issue 3 | Original Article | 255 | Copyright © March 2025
Immunotherapy utilizing immune checkpoint inhibitors (ICIs) such as PD-1, PD-L1, and CTLA-4 inhibitors has revolutionized cancer therapy by enhancing T cell recognition and attack against cancer ...
Read MoreComparative Efficacy of Intralesional Steroid Injections vs Cryotherapy for the Treatment of Alopecia Areata
March 2025 | Volume 24 | Issue 3 | Original Article | 294 | Copyright © March 2025
Introduction: The precise etiology of alopecia areata (AA) remains unclear. Various treatments, including corticosteroids, minoxidil, immunotherapy, and phototherapy, have shown ...
Read MoreDifferentiating and Managing Cutaneous Lupus Erythematosus-Associated Alopecia and Patchy Alopecia Areata: Therapeutic Insights From Case Studies
March 2025 | Volume 24 | Issue 3 | Case Reports | 324 | Copyright © March 2025
Cutaneous lupus erythematosus (CLE) is an autoimmune disease with diverse clinical manifestations, including patchy hair lossresembling alopecia areata (AA). This report describes tw...
Read MoreDisparities in Alopecia Areata and Vitiligo FDA-Approved Therapies in Medicaid Formularies
March 2025 | Volume 24 | Issue 3 | Editorials | e17 | Copyright © March 2025
Co-occurring Melanoma in an Active Area of Vitiligo in Skin of Color
February 2025 | Volume 24 | Issue 2 | Case Reports | 205 | Copyright © February 2025
The association between vitiligo and melanoma is complex. While the incidence of vitiligo in patients with melanoma is higher, the risk for the reverse, ie, the development of melanoma in a patie...
Read MoreReview of Baricitinib in the Treatment of Alopecia Areata
September 2023 | Volume 22 | Issue 9 | Original Article | 935 | Copyright © September 2023
Background: Alopecia areata (AA) is a debilitating autoimmune disease that results in non-scarring hair loss. Baricitinib is the Food and Drug Administration (FDA) approved treat...
Read MoreReview of Superficial Cryotherapy for the Treatment of Alopecia Areata
August 2023 | Volume 22 | Issue 8 | Original Article | 802 | Copyright © August 2023
Cryotherapy has recently been examined as a potential treatment for alopecia areata (AA). AA is classically managed with intralesional or systemic steroids but relapse rates among those with long...
Read MoreRefractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
December 2022 | Volume 21 | Issue 12 | Case Reports | 1366 | Copyright © December 2022
Background: In the last several years, oral tofacitinib has become an increasingly utilized off-label treatment option for immune-mediated skin conditions such as alopecia areata (AA)...
Read MoreThe Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review
October 2022 | Volume 21 | Issue 10 | Original Article | 1070 | Copyright © October 2022
Background: Approximately 30% to 40% of alopecia areata (AA) patients have atopic dermatitis. Studies suggest that antihistamines and dupilumab may be effective treatments; however, t...
Read MoreRetrospective Study of Covid Related Hair Loss
July 2022 | Volume 21 | Issue 7 | Original Article | 724 | Copyright © July 2022
The Novel Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus two and primarily affects the epithelium of the airways. Multiple cutaneous manifestations of COVID-...
Read MoreA Case of Late-Onset Alopecia Areata
April 2022 | Volume 21 | Issue 4 | Case Reports | 420 | Copyright © April 2022
Alopecia areata (AA) is a condition characterized by nonscarring hair loss. Cases of alopecia areata are most commonly seen in patients under age 30 and are frequently idiopathic. In this report, we d...
Read MoreSuccessful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib
July 2018 | Volume 17 | Issue 7 | Case Reports | 800 | Copyright © July 2018
Alopecia areata is an autoimmune disease involving the hair follicle with a chronic, relapsing course. Tofacitinib...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
